Borghaei H, Langer CJ, Paz‐Ares L, et al. - Among patients suffering from advanced/metastatic non–small cell lung cancer (NSCLC) negative for programmed death ligand 1 (PD‐L1) (ie, a tumor proportion score < 1%), researchers assessed outcomes with pembrolizumab plus chemotherapy compared to chemotherapy alone by pooling data from 3 randomized controlled trials. PD‐L1‒negative tumors were present in 444 of the 1,328 patients (33.4%) who were enrolled from across the three trials. Findings showed that response and survival improvements, along with manageable safety were afforded by pembrolizumab plus chemotherapy vs chemotherapy alone in PD‐L1‒negative advanced/metastatic NSCLC, and experts concluded pembrolizumab plus chemotherapy as a standard‐of‐care first‐line therapy for patients suffering from advanced NSCLC, irrespective of PD‐L1 expression.